10-Year safety watch for seizure drug in rare genetic disorder

NCT ID NCT02962414

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study follows patients with tuberous sclerosis complex (TSC) who have seizures that are hard to control with standard medications. It monitors the long-term safety of the drug everolimus over approximately 10 years in about 206 patients who benefited from it in a previous trial. The main goal is to track side effects and confirm that patients continue to see benefit from ongoing treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Atlantic Health Systems

Morristown, New Jersey, 07962, United States
Childrens Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Cinn Children Hosp Medical Center

Cincinnati, Ohio, 45229-3039, United States
Connecticut Childrens Medical Cntr

Hartford, Connecticut, 06106, United States
David Geffen School of Medicine at UCLA

Los Angeles, California, 90005-1752, United States
Minnesota Epilepsy Group

Saint Paul, Minnesota, 55102, United States
Novartis Investigative Site

Sydney, New South Wales, 2031, Australia
Novartis Investigative Site

Nedlands, Western Australia, 6009, Australia
Novartis Investigative Site

Brussels, 1090, Belgium
Novartis Investigative Site

Brussels, 1200, Belgium
Novartis Investigative Site

Ghent, 9000, Belgium
Novartis Investigative Site

Leuven, 3000, Belgium
Novartis Investigative Site

Vancouver, British Columbia, V6H 3V4, Canada
Novartis Investigative Site

Cali, Valle del Cauca Department, 760032, Colombia
Novartis Investigative Site

Amiens, 80054, France
Novartis Investigative Site

Bron, 69677, France
Novartis Investigative Site

Lille, 59037, France
Novartis Investigative Site

Marseille, 13885, France
Novartis Investigative Site

Strasbourg, 67000, France
Novartis Investigative Site

Budapest, 1145, Hungary
Novartis Investigative Site

Bari, BA, 70124, Italy
Novartis Investigative Site

Bologna, BO, 40139, Italy
Novartis Investigative Site

Pavia, PV, 27100, Italy
Novartis Investigative Site

Roma, RM, 00161, Italy
Novartis Investigative Site

Siena, SI, 53100, Italy
Novartis Investigative Site

Suita, Osaka, 565 0871, Japan
Novartis Investigative Site

Shizuoka, Shizuoka, 4208688, Japan
Novartis Investigative Site

Okayama, 7008558, Japan
Novartis Investigative Site

Osaka, 5340021, Japan
Novartis Investigative Site

Guadalajara, Jalisco, 44280, Mexico
Novartis Investigative Site

Warsaw, 04-730, Poland
Novartis Investigative Site

Samara, Samara Oblast, 443095, Russia
Novartis Investigative Site

Moscow, 119991, Russia
Novartis Investigative Site

Moscow, 127412, Russia
Novartis Investigative Site

Voronezh, 394024, Russia
Novartis Investigative Site

Seoul, Korea, 03080, South Korea
Novartis Investigative Site

Seoul, 03722, South Korea
Novartis Investigative Site

Seoul, 06351, South Korea
Novartis Investigative Site

Donostia / San Sebastian, Gipuzkoa, 20014, Spain
Novartis Investigative Site

Barcelona, 08035, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Madrid, 28041, Spain
Novartis Investigative Site

Seville, 41013, Spain
Novartis Investigative Site

Valencia, 46026, Spain
Novartis Investigative Site

Kaohsiung City, 83301, Taiwan
Novartis Investigative Site

Tainan, 704302, Taiwan
Novartis Investigative Site

Taipei, 10002, Taiwan
Novartis Investigative Site

Bangkok, 10330, Thailand
Novartis Investigative Site

Bangkok, 10400, Thailand
Novartis Investigative Site

Bangkok, 10700, Thailand
Novartis Investigative Site

Istanbul, Fatih, 34093, Turkey (Türkiye)
Novartis Investigative Site

Ankara, Yenimahalle, 06500, Turkey (Türkiye)
Novartis Investigative Site

Birmingham, West Midlands, B15 2TH, United Kingdom
Novartis Investigative Site

Buckinghamshire, SL9 0RJ, United Kingdom
Novartis Investigative Site

Cambridge, CB2 0QQ, United Kingdom
Novartis Investigative Site

Liverpool, L12 2AP, United Kingdom
Novartis Investigative Site

London, SW17 0QT, United Kingdom
Novartis Investigative Site

London, WC1N 3JH, United Kingdom
Novartis Investigative Site

Sheffield, S10 2TH, United Kingdom
Novartis Investigative Site

York, YO31 7EX, United Kingdom
Oregon Health Sciences University

Portland, Oregon, 97239, United States
Rady Children s Hospital

San Diego, California, 92123, United States
TGen APNNA

Phoenix, Arizona, 85012, United States
Texas Childrens Hospital

Houston, Texas, 77030, United States
Texas Scottish Rite Hos for Child

Dallas, Texas, 75219, United States
UCSF Benioff Children s Hospital

Oakland, California, 94609, United States
University of Chicago Medical Center

Chicago, Illinois, 60637, United States
University of Colorado School of Medicine

Aurora, Colorado, 80045, United States

Conditions

Explore the condition pages connected to this study.

TUBEROUS SCLEROSIS COMPLEX